NEW DELHI: In a move aimed at reshaping how epilepsy is managed in India, the All India Institute of Medical Sciences (AIIMS), New Delhi has introduced a low-cost advanced diagnostic system designed to improve the safety and precision of treatment for patients suffering from seizure disorders.
The new initiative focuses on therapeutic drug monitoring and advanced laboratory testing, allowing doctors to closely track how anti-epileptic medicines are processed in a patient’s body. By generating detailed drug-response data, the system helps clinicians fine-tune dosages instead of relying on standardised prescriptions that may not suit every individual.
Hospital officials said the primary goal is to reduce treatment-related risks that arise when medication levels are either too high or too low. In epilepsy care, such imbalances can lead to breakthrough seizures, unwanted side effects, or long-term toxicity affecting organs such as the liver and kidneys.
What sets the programme apart is its cost structure. The testing model has been developed in a way that makes it significantly cheaper than conventional private laboratory services, bringing advanced monitoring within reach of a much wider patient base. For many patients undergoing long-term epilepsy treatment, repeated testing outside government facilities often becomes financially unsustainable.
Doctors at AIIMS explained that the system enables a more personalised approach to care by identifying the optimal therapeutic range of medication for each patient individually. This reduces trial-and-error prescribing and helps stabilise patients faster, particularly those with drug-resistant or complex forms of epilepsy.
The initiative also strengthens clinical decision-making by providing real-time biochemical insights, which can guide neurologists in adjusting treatment plans more accurately during follow-ups. This is especially critical in cases where patients are on multiple anti-seizure drugs simultaneously.
Experts associated with the programme highlighted that epilepsy remains one of the most common neurological disorders in India, yet access to continuous monitoring remains limited in many parts of the country. The new system is expected to bridge part of this gap by making advanced monitoring more routine and affordable within a public healthcare setting.
Beyond individual treatment benefits, AIIMS officials believe the model could serve as a template for other government hospitals looking to integrate precision medicine into neurology services, particularly for chronic conditions requiring long-term drug management.
With this step, AIIMS continues to expand its focus on combining affordability with innovation, aiming to improve treatment outcomes while reducing the clinical and financial burden on patients and families dealing with epilepsy.
